Generation of new pancreatic beta cells
The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.
1. A method of treating type 1 and 2 diabetes, comprising the step of:
administering to a subject a therapeutically effective amount of a peptide that has Reg receptor binding activity, wherein the peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO:14.
2. The method of claim 1 , wherein an immune modulator is administered before and/or in parallel with the administration of the therapeutically effective amount of the peptide that has Reg receptor binding activity.
3. The method of claim 2 , wherein the immune modulator is administered at repeat dosages for the protection of newly-formed beta cells.
4. The method of claim 2 , wherein the immune modulator is a general immunosuppressant agent or an antibody targeted to lymphocytes.
5. The method of claim 1 , wherein a period of glucose control is optimized before the administration of the therapeutically effective amount of the peptide that has Reg receptor binding activity; wherein the glucose control is optimized for glucose levels of between 100 to 200 mg/dl or the glucose control is optimized to prevent glucose levels from falling below 70 mg/dl.
6. The method of claim 5 , wherein the period of glucose control is at least 4 weeks.
7. The method of claim 1 , wherein the subject's insulin dose is decreased based on glucose levels to prevent an episode of hypoglycemia.
8. The method of claim 1 , wherein the peptide that has Reg receptor binding activity is administered through oral, intravenous, intra-arterial, or subcutaneous delivery.
9. The method of claim 1 , wherein the peptide that has Reg receptor binding activity is administered directly to the pancreas or the liver.
10. The method of claim 1 , wherein the peptide that has Reg receptor binding activity is administered in combination with another diabetic agent.
11. The method of claim 10 , wherein the other diabetic agent is a form of insulin, liraglutide, exenatide, sitagliptin, saxagliptin, linagliptin, pramlintide, acarbose, orlistat, colesevelam, bromocriptine, biguanide, metformin, dapagliflozin, canagliflozin, a sulfonylurea, a meglitinide, a GLP-1 receptor analog, a DPP-4 inhibitor, a thiazolidinedione, an SGLT2 inhibitor, an anti-inflammatory agent, or vitamin D.
12. The method of claim 10 , wherein administration of the other diabetic agent is tapered off or reduced based on daily glucose values.
13. The method of claim 12 , wherein the other diabetic agent is insulin and is reduced by about 0.5-2.0% per day.
14. The method of claim 1 , wherein the subject is diabetes-drug naïve.
15. The method of claim 1 , wherein the peptide is administered at intervals to maintain a minimum number of beta cells for normal glucose metabolism.